Transposagen Biopharmaceuticals doesn't make a big public fuss about its pharmaceutical collaborations – the Lexington, Kentucky-based company has relationships with 19 out of the top 20 big pharma – but the Johnson & Johnson subsidiary Janssen Biotech is happy to tout the promise of its new partner's technology.

Calico licenses UT Southwestern compounds from 2M; MabVax gets into CAR T business with MSKCC and Juno; and Kolltan buys Xetrios.

Elan will spend $1 billion of the $3.25 billion one-off payment it is receiving from Biogen Idec for the return of rights to the blockbuster multiple sclerosis drug Tysabri to buy back around a 16% stake in the Irish company.